Characteristics | Number (percent) |
---|---|
Baseline age in year (n = 1196) | |
 15–20 | 149 (12.5) |
 21–30 | 473 (39.5) |
 31–40 | 388 (32.4) |
 41–50 | 128 (10.7) |
 ≥51 | 58 (4.8) |
Sex (n = 1196) | |
 Female | 666 (55.7) |
 Male | 530 (44.3) |
Baseline functional status (n = 1047) | |
 Working | 651 (62.2) |
 Ambulatory | 345 (33.0) |
 Bedridden | 51 (4.8) |
Baseline WHO clinical stage (1196) | |
 Stage 1 | 61 (5.1) |
 Stage 2 | 180 (15.0) |
 Stage 3 | 809 (67.7) |
 Stage 4 | 146 (12.2) |
First treatment class (n = 1196) | |
 AZT-3TC | 732 (61.2) |
 D4t-3TC | 36 (3.0) |
 D4t (30) | 424 (35.5) |
 D4t (40) TDF-ddl | 3 (0.3) 1 (0.08) |
Baseline CD4 count (n = 1196) | |
 <200 | 919 (76.8) |
 200–349 | 218 (18.2) |
 350–499 | 32 (2.7) |
 ≥500 | 27 (2.3) |
Average CD4 count increment (compared to the baseline)a | |
 At 6 month (n = 861) | 228 (60.26) |
 At 1 year (n = 787) | 232 (60.66) |
 At 2 year (n = 701) | 229 (60.33) |
 At 3 year (n = 569) | 264 (63.73) |
 At 4 year (n = 378) | 303 (66.87) |